AstraZeneca Pharmaceuticals LP

1904 articles with AstraZeneca Pharmaceuticals LP

• 

  Akero Therapeutics Launches with $65 Million Series A to Battle NASH

  6/25/2018

  Akero Therapeutics, headquartered in Cambridge, Massachusetts, closed on a $65 million Series A financing round.
• 

  On “The Longest Day,” A Look at Alzheimer’s Clinical Trials

  6/21/2018

  June is Alzheimer’s & Brain Awareness Month and June 21 is dubbed “The Longest Day,” which focuses on raising awareness of Alzheimer’s disease.
• 

  Organ-on-a-Chip Company Emulate Closes on $36 Million Series C Financing

  6/19/2018

  Boston-based Emulate closed on a Series C round worth $36 million.
• 

  With Headway in NASH, Madrigal Pharma is Considering Sale

  6/14/2018

  Reportedly, Madrigal Pharmaceuticals is considering a sale. After receiving interest from other big drug companies, the nine-employee company is evaluating its options.

• Update on Phase 3 Clinical Trials of Lanabecestat for Alzheimer's Disease

  6/12/2018

  Independent data monitoring committee advises lanabecestat is unlikely to meet primary endpoints, leading to decision to discontinue these trials

• 

  First International NASH Day is a Call to Action

  6/12/2018

  The prevalence of nonalcoholic steatohepatitis (NASH) is increasing across the globe and is expected to be the leading indication for liver transplants by 2020. Despite that, awareness of the disease is somewhat low.
• 

  Eli Lilly and AstraZeneca Abandon Alzheimer’s Drug

  6/12/2018

  Yet another drug for Alzheimer’s has been tossed in the trash. AstraZeneca and Eli Lilly announced they have abandoned two late-stage clinical trials of lanabecestat for Alzheimer’s disease.

• Seroquel Stepping Stone: How Luye Will Use Seroquel to Expand in Emerging Markets

  6/7/2018

  The $538 million acquisition by Luye Pharma Group Ltd. (HKSE:2186) of Seroquel quetiapine fumarate from AstraZeneca plc (LSE:AZN; NYSE:AZN) will lay the commercial groundwork in new emerging markets for the Chinese pharma's internal CNS pipeline.

• 

  Pfizer Pays BioMarin Pharma $20 Million Milestone

  6/7/2018

  BioMarin Pharmaceutical received $20 million in milestone payments from Pfizer after the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) approved its applications for talazoparib.

• Orchard Therapeutics Announces Appointments of Marc Dunoyer and Charlie Rowland to Board of Directors

  6/7/2018

  Orchard Therapeutics today announced the appointments of Marc Dunoyer and Charlie Rowland to its board of directors as independent directors.

• Advaxis Announces Prioritization of Product Portfolio and Reports Fiscal 2018 Second Quarter Financial Results

  6/7/2018

  Advaxis, Inc. today announced a new prioritization of its product portfolio, as well as financial results and business highlights for the three months ended April 30, 2018.

• Results From AstraZeneca Study Presented Today at ASCO

  6/4/2018

  DiviTum results from a large AstraZeneca study are presented today at the ASCO meeting in Chicago, the largest cancer congress in the world.

• LYNPARZA® (olaparib) in Combination with Abiraterone Delayed Disease Progression in Metastatic Castration-Resistant Prostate Cancer

  6/4/2018

  AstraZeneca and Merck presented data which showed clinical improvement in median radiologic progression-free survival (rPFS) with LYNPARZA® (olaparib) in combination with abiraterone compared to abiraterone monotherapy, a current standard of care, in metastatic castration-resistant prostate cancer (mCRPC).

• 

  Madrigal Pharma’s NASH Drug Has Positive Results in Phase II

  5/31/2018

  Madrigal Pharmaceuticals announced positive topline data from its Phase II clinical trial of MGL-3196 in patients with biopsy-proven non-alcoholic steatohepatitis (NASH).
• 

  AstraZeneca’s Fasenra Fails a Second Phase III COPD Trial

  5/30/2018

  AstraZeneca’s add-on asthma treatment Fasenra has failed a second Phase III trial this month.
• 

  NASH Pipelines Face Questions as Drugs Near Potential Approval

  5/25/2018

  There are dollar signs in the treatment of nonalcoholic steatohepatitis (NASH). The market is pegged to hit $25 billion by 2026 and companies are flooding the developmental pipeline with potential treatments for a disease that has no approved therapies in the United States.

• IMFINZI® (Durvalumab) Significantly Improves Overall Survival in the Phase III Pacific Trial for Unresectable Stage III Non-Small Cell Lung Cancer

  5/25/2018

  IMFINZI met the second primary endpoint of overall survival which was both statistically significant and clinically meaningful at a planned interim analysis

• 

  AstraZeneca’s Imfinzi Shows Positive Overall Survival Results in Lung Cancer Trial

  5/25/2018

  AstraZeneca and its research-and-development unit MedImmune, announced positive overall survival (OS) data for its Phase III PACIFIC trial of Imfinzi (durvalumab) in patients with unresectable Stage III non-small cell lung cancer (NSCLC).
• 

  Brii Biosciences Launches with $260 Million, a Partnership with Vir Biotech, and Other Relationsh...

  5/24/2018

  Brii Biosciences is launching to accelerate the development and delivery of breakthrough drugs in China with $260 million in financial backing.

• Bicycle Therapeutics Expands Strategic Partnership with AstraZeneca

  5/24/2018

  New programs added in respiratory and cardio-metabolic diseases